Concepedia

Mutiah Apatira

MA

Statistics

Publications

6

Citations

548

H-Index

6

Active since

2001

Affiliations

Pharmacyclics (United States)(Current)

AbbVie (United States)

Mutiah Apatira is an author at Pharmacyclics (United States) specializing in medicine, oncology, and tyrosine kinase inhibitors.

Publications per year

2001–2023

6

Publications

6

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)

Louise Kelly, Jin‐Chen Yu, Christina Boulton et al. · Cancer Cell · 2002 · 307 citations · Full text

, , +10

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma

Hsu-Ping Kuo, Sidney Hsieh, Karl J. Schweighofer et al. · Blood · 2015 · 64 citations

, , +8

Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Hsu-Ping Kuo, Scott A. Ezell, Karl J. Schweighofer et al. · Molecular Cancer Therapeutics · 2017 · 64 citations · Full text

, , +15

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.

Hsu-Ping Kuo, Scott A. Ezell, Sidney Hsieh et al. · PubMed · 2016 · 55 citations · Full text

, , +17

Efficacy of the Novel Selective Platelet-Derived Growth Factor Receptor Antagonist CT52923 on Cellular Proliferation, Migration, and Suppression of Neointima following Vascular Injury

Jin‐Chen Yu, Nathalie A. Lokker, Stanley J. Hollenbach et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 39 citations

, , +10

1–5 of 6